Issuance of Convertible Notes & Warrants for up to $46m
Filed with ASX · · 9 pages · English
Summary by 6ix AI
Imugene Ltd has announced the issuance of Convertible Notes and Warrants to CVI Investments Inc. to raise significant capital. This capital raising is subject to shareholder approval and certain conditions being met before completion. The funding is expected to extend Imugene's cash runway into the future, enhancing its ability to advance its clinical pipeline.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Imugene
- Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
- onCARlytics Trial Doses First Patient in IT Combination Arm
- Imugene Opens First Australian Site for azer-cel Trial
- Complete Response in MAST Study Maintained Over Two Years
- Imugene Receives Orphan Drug Designation for VAXINIA
Later from Imugene
- First Australian Patient Dosed in Phase 1b azer-cel Trial
- Imugene Receives $11.7m R&D Tax Refund
- Imugene Receives A$20 million for Convertible Notes Issuance
- Azer-cel demonstrates two additional Complete Responses
- Imugene OnCARlytics Patent Allowance in China
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene